Skip to main content

Advertisement

SpringerLink
Log in

Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and visual outcomes following different intravitreal anti-vascular endothelial growth factor (VEGF) treatments in eyes with subretinal neovascular membrane (SRNVM) due to type 2 proliferative macular telangiectasia (Mac Tel 2).

Materials and methods

A total of 38 eyes of 34 patients who underwent intravitreal aflibercept (IVA), intravitreal ranibizumab (IVR), or intravitreal bevacizumab (IVB) injections secondary to SRNVM due to type 2 proliferative MacTel were retrospectively reviewed. The CMT, central macular volume (CMV), best corrected visual acuity (BCVA), and SFCT were evaluated at baseline and at 2 weeks, at 1 month, and at final visits following treatment. Spectral-domain optical coherence tomography and enhanced depth optical coherence tomography were used for the analysis.

Results

The mean age of the patients was 58.34 ± 12.48 years (range, 27–79 years). The mean follow-up time was 15.97 ± 6.79 months (range 5–32 months). The mean BCVA showed a statistically significant increase in each group (< 0.001). There was no statistically significant difference in BCVA changes between groups in follow-up periods. There was a significant decrease in CMT following IVA (326.4 ± 168.03 μm to 236 ± 58.33 μm) and IVB (383.71 ± 156.79 μm to 343.85 ± 146.25 μm) (p < 0.001, p = 0.004, respectively) whereas no significant decrease in CMT was observed following IVR (374.57 ± 124.28 μm to 339.71 ± 126.10 μm) (p = 0.65) between baseline and final visit. The SFCT significantly decreased following both IVB and IVR treatments (p = 0.009, p = 0.03, respectively).

Conclusions

The IVA, IVR, and IVB were found to be effective with regards to anatomical and visual outcomes in proliferative Mac Tel type 2 patients related with SRNVM. Patients receiving both IVA and IVB needed less injections compared to patients who received IVR. Moreover, IVB and IVR lead to significant decrease in SFCT whereas IVA did not show significant effect on SFCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gass JD, Oyakawa RT (1982) Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 100:769–780

    Article  CAS  Google Scholar 

  2. Wu L, Evans T, Arevalo JF (2013) Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2). Surv Ophthalmol 58:536–559

    Article  Google Scholar 

  3. Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis: Update of classification and follow-up study. Ophthalmology 100:1536–1546

    Article  CAS  Google Scholar 

  4. Yannuzzi LA, Bardal AM, Freund KB et al (2006) Idiopathic macular telangiectasia. Arch Ophthalmol 124:450–460

    Article  Google Scholar 

  5. Eliassi-Rad B, Green WR (1999) Histopathologic study of presumed parafoveal telangiectasis. Retina 19:332–335

    Article  CAS  Google Scholar 

  6. Hirano Y, Yasukawa T, Usui Y, Nozaki M, Ogura Y (2010) Indocyanine green angiography-guided laser photocoagulation combined with sub-Tenon’s capsule injection of triamcinolone acetonide for idiopathic macular telangiectasia. Br J Ophthalmol 94:600–605

    Article  Google Scholar 

  7. Chopdar A (1978) Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser. Br J Ophthalmol 62:243–250

    Article  CAS  Google Scholar 

  8. Cakir M, Kapran Z, Basar D et al (2006) Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur J Ophthalmol 16:711–717

    Article  CAS  Google Scholar 

  9. Li KK, Goh TY, Parsons H, Chan WM, Lam DS (2005) Use of intravitreal triamcinolone acetonide injection in unilateral idiopathic juxtafoveal telangiectasis. Clin Exp Ophthalmol 33:542–544

    Article  Google Scholar 

  10. Martinez JA (2003) Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 121:1658–1659

    Article  Google Scholar 

  11. Terauchi G, Matsumoto CS, Shinoda K et al (2014) Pars plana vitrectomy combined with focal endolaser photocoagulation for idiopathic macular telangiectasia. Case Rep Med 2014:786578

    Article  Google Scholar 

  12. Ciarnella A, Verrilli S, Fenicia V et al (2012) Intravitreal ranibizumab and laser photocoagulation in the management of idiopathic juxtafoveolar retinal telangiectasia type 1: a case report. Case Rep Ophthalmol 3:298–303

    Article  Google Scholar 

  13. Rouvas A, Malamos P, Douvali M, Ntouraki A, Markomichelakis NN (2013) Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia. Clin Ophthalmol 7:1357–1362

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Shibeeb O, Vaze A, Gillies M, Gray T (2014) Macular oedema in idiopathic macular telangiectasia type1 responsive to aflibercept but not bevacizumab. Case Rep Ophthalmol Med 2014:219792

    PubMed  PubMed Central  Google Scholar 

  15. Gamulescu MA, Walter A, Sachs H, Helbig H (2008) Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246:1189–1193

    Article  CAS  Google Scholar 

  16. Koay CL, Chew FL, Visvaraja S (2011) Bevacizumab and type 1 idiopathic macular telangiectasia. Eye (Lond) 25:1663–1665

    Article  CAS  Google Scholar 

  17. Matsumoto Y, Yuzawa M (2010) Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 54:320–324

    Article  CAS  Google Scholar 

  18. Moon BG, Kim YJ, Yoon YH, Lee JY (2012) Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 250:1697–1699

    Article  Google Scholar 

  19. Moon SJ, Berger AS, Tolentino MJ, Misch DM (2007) Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. Ophthalmic Surg Lasers Imaging 38:164–166

    Article  Google Scholar 

  20. Takayama K, Ooto S, Tamura H et al (2010) Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia. Eye (Lond) 24:1492–1497

    Article  CAS  Google Scholar 

  21. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B (2012) Idiopathic macular telangiectasia. 2006. Retina 32(Suppl 1):450–460

    Article  Google Scholar 

  22. Newman E, Reichenbach A (1996) The Muller cell: a functional element of the retina. Trends Neurosci 19:307–312

    Article  CAS  Google Scholar 

  23. Tout S, Chan-Ling T, Hollander H, Stone J (1993) The role of Muller cells in the formation of the blood-retinal barrier. Neuroscience 55:291–301

    Article  CAS  Google Scholar 

  24. Charbel Issa P, Finger RP, Holz FG, Scholl HP (2008) Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 92:941–945

    Article  CAS  Google Scholar 

  25. Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HP, Holz FG (2011) Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 151:876–886

    Article  Google Scholar 

  26. Charbel Issa P, Holz FG, Scholl HP (2007) Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 114:1736–1742

    Article  Google Scholar 

  27. Maia OO Jr, Bonanomi MT, Takahashi WY, Nascimento VP, Takahashi BS (2007) Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol 144:296–299

    Article  Google Scholar 

  28. Matt G, Sacu S, Ahlers C, Schutze C, Dunavoelgyi R, Prager F et al (2010) Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye (Lond) 24:1535–1541

    Article  CAS  Google Scholar 

  29. Raza S, Toklu Y, Anayol MA, Şimşek Ş, Özkan B, Altıntaş AK (2011) Comparison between efficacy of triamcinolone acetonide and bevacizumab in a case with type 2A idiopathic parafoveal telangiectasia. Turk J Ophthalmol 41:6–9

    Article  Google Scholar 

  30. Toy BC, Koo E, Cukras C, Meyerle CB, Chew EY, Wong WT (2012) Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial. Retina 32:996–1006

    Article  CAS  Google Scholar 

  31. Veloso CE, Vianna RN, Pelayes DE, Nehemy MB (2013) Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia. Ophthalmic Res 49:205–208

    Article  CAS  Google Scholar 

  32. Narayanan R, Majji AB, Hussain N et al (2008) Characterization of idiopathic macular telangiectasia type 2 by fundus fluorescein angiography in Indian population. Eur J Ophthalmol 18:587–590

    Article  CAS  Google Scholar 

  33. Nalcı H, Şermet F, Demirel S, Özmert E (2017) Optical Coherence Tomography Angiography Findings in Type-2 Macular Telangiectasia. Turk J Ophthalmol 47(5):279–284. https://doi.org/10.4274/tjo.68335

    Article  PubMed  PubMed Central  Google Scholar 

  34. Wu L (2015) When is macular edema not macular edema? An update on macular telangiectasia type 2. Taiwan J Ophthalmol 5(4):149–155. https://doi.org/10.1016/j.tjo.2015.09.001

    Article  PubMed  PubMed Central  Google Scholar 

  35. Narayanan R, Chhablani J, Sinha M et al (2012) Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina 32:2001–2005

    Article  CAS  Google Scholar 

  36. Mandal S, Venkatesh P, Abbas Z et al (2007) Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 245:1825–1829

    Article  CAS  Google Scholar 

  37. Khodabande A, Roohipoor R, Zamani J et al (2019) Management of Idiopathic Macular Telangiectasia Type 2. Ophthalmol Therapy 8(2):155–175

    Article  Google Scholar 

  38. Karagiannis D, Georgalas I, Ladas I, Eustratios P, Mitropoulos P (2009) A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis. Clin Interv Aging 4:63–65

    PubMed  PubMed Central  Google Scholar 

  39. Papadopoulos Z (2019) Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol 29(4):368–378

    Article  Google Scholar 

  40. Davidorf FH, Pressman MD, Chambers RB (2004) Juxtafoveal telangiectasis-a name change? Retina 24(3):474–478

    Article  Google Scholar 

  41. Gass JD (2003) Chorioretinal anastomosis probably occurs infrequently in type 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 121(9):1345–1346

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Health Sciences, Beyoglu Eye Training and Research Hospital, Bereketzade Mah, Bereketzade Sok. No: 2, Beyoğlu, 34421, Istanbul, Turkey

    Buğra Karasu

  2. Department of Ophthalmology, University of Health Sciences, Trabzon Kanuni Training and Research Hospital, Trabzon, Turkey

    Betul Onal Gunay

Authors
  1. Buğra Karasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Betul Onal Gunay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Buğra Karasu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karasu, B., Gunay, B.O. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 258, 99–106 (2020). https://doi.org/10.1007/s00417-019-04520-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-019-04520-x

Keywords

Search

Navigation